ProNAi Therapeutics, Inc. (NASDAQ:SRRA) Director James N. Topper purchased 5,925,926 shares of the stock in a transaction dated Tuesday, February 14th. The shares were purchased at an average price of $1.35 per share, with a total value of $8,000,000.10. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

ProNAi Therapeutics, Inc. (NASDAQ:SRRA) traded down 2.11% during midday trading on Thursday, reaching $1.39. The stock’s 50 day moving average price is $1.44 and its 200 day moving average price is $1.63. The firm’s market cap is $42.21 million. ProNAi Therapeutics, Inc. has a 1-year low of $1.31 and a 1-year high of $8.24.

“ProNAi Therapeutics, Inc. (SRRA) Director Purchases $8,000,000.10 in Stock” was originally reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be read at http://www.dailypolitical.com/2017/02/16/pronai-therapeutics-inc-srra-director-purchases-8000000-10-in-stock.html.

Separately, Zacks Investment Research downgraded shares of ProNAi Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, November 14th.

ProNAi Therapeutics Company Profile

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

5 Day Chart for NASDAQ:SRRA

Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.